Utah Medical Products Inc (UTMD) financials

NASDAQ · Health Care

$68.08 +1.91% Close Oct 30, 2026 Live

Utah Medical Products revenue and earnings by year

Utah Medical Products's revenue was $38.5 million in the fiscal year to December 31, 2025, down 5.8% from the year before. Net income was $11.3 million, 29.3% of revenue. Since the fiscal year to December 31, 2016, revenue has shrunk 0.2% a year on average.

RevenueNet income
$20.0M$40.0M
2016201720182019202020212022202320242025

Fiscal years, each labelled by the calendar year it ended in.

Income statement, the last 10 fiscal years

In millions of US dollars except per-share figures. Each column is a fiscal year, named by the month it ended.
Fiscal year toDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
Revenue39415052494247424139
Revenue growth-5.8%-18.6%-3.9%6.6%16.3%-10.1%11.7%1.4%5.4%—
Gross profit22243032312629262624
Gross margin57.1%59.0%59.8%61.6%63.0%60.6%62.8%62.6%63.7%60.3%
Operating income11141720191418191916
Operating margin29.6%33.2%33.4%37.9%38.5%32.5%37.6%44.5%45.9%41.2%
Net income1114171615111519912
Net margin29.3%33.9%33.1%31.5%30.1%25.6%31.4%44.2%20.5%30.9%
Diluted EPS$3.48$3.96$4.57$4.51$4.05$2.94$3.94$4.95$2.29$3.22
Free cash flow14152220211917161511

Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open UTMD in Markets.

How Utah Medical Products makes money

Revenue by segment in the quarter to June 30, 2026, as the company reports it.

SegmentRevenueShare
Gynecology Electrosurgery Urology$4.28M50.2%
Neonatal$1.92M22.5%
Blood Pressure Monitoring & Accessories$1.26M14.8%
Obstetrics$1.07M12.5%

See also: UTMD valuation and P/E history · UTMD returns

No forecast, no recommendation. This page describes Utah Medical Products Inc from published data; it is not advice to buy, sell or hold any security.

Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.